An explosion in demand for your drug product can be a great problem to have. But if you haven’t secured your supply chain and can’t adequately scale up production to meet the increased demand, you could be left unable to capitalize on it. Following the unprecedented surge in popularity of GLP‑1 agonists, manufacturers faced this exact challenge — prompting the FDA and EMA to declare shortages.
In addition to unexpected demand, there are numerous other circumstances that can result in a supply shortage. Fortunately, the risk of getting into these scenarios can be proactively mitigated.
To build a more resilient supply chain, Chemistry, Manufacturing, and Controls (CMC) and procurement teams can build redundancy by qualifying a second API supplier (often called “dual sourcing”). This choice requires upfront investment, regulatory planning, and additional quality oversight, which, in the short term, can be difficult to obtain.
This article explores the risks of single‑source dependencies, indicators that signal when to qualify a second API supplier, key regulatory considerations, and where dual sourcing delivers the greatest value across the product lifecycle.
The Risks of Relying on a Single API Supplier
There are several vulnerabilities that arise when relying on a single source for critical APIs.
Natural Disasters
Fires, hurricanes, earthquakes, or other natural disasters at a sole API manufacturing facility can instantly cut off supply, triggering immediate and often prolonged drug shortages, particularly when only one supplier or one geographic region supports global demand. Overreliance on a single site amplifies disruption risk, as any delay or shutdown leaves no alternative source to absorb the impact, a pattern repeatedly observed in high-volume and critical medicines.
Regulatory and Compliance Issues
GMP non-compliance, failed inspections, and warning letters at a sole-source API supplier leaves you with no fallback options and can halt drug production for months. With the FDA increasing the volume of inspections, this is a major risk for manufacturers, even in well-regulated markets.
Capacity Constraints
Capacity constraints at a sole API supplier can quickly become a bottleneck as demand increases, particularly during transitions from clinical to commercial scale, when entering new markets, or sudden unforeseen surges in popularity. Without a qualified backup supplier, manufacturers may face extended lead times, or missed production windows, a risk that threatens high-volume products or drugs with predictable seasonal demand spikes.
Business Continuity Risks
Business and economic pressures, including mergers and acquisitions, financial instability, strategic reprioritization, or limited commercial incentive (e.g., generics), can lead a sole API supplier to abruptly discontinue production. When only one source is approved, such decisions force manufacturers into urgent, stressful, and time-consuming replacement efforts.
How to Tell When It’s Time to Qualify a Second API Source
The above vulnerabilities can delay clinical testing and drug product supply, ultimately lengthening timelines and causing lost revenue. While the cost and effort of qualifying a second API source can seem substantial, they are a preventive measure that can save you money and time in the long term.
There may also be concerning red flags, such as compliance issues, that should signal to you that it’s time to qualify a secondary supplier sooner rather than later.
- Recurring quality or compliance issues, such as repeated deviations, out-of-specification results, warning letters, slow CAPA closure, or unresolved audit findings, signal declining supplier reliability and should trigger contingency planning before a major compliance event halts supply.
- Extending lead times, inconsistent deliveries, or allocation indicate capacity constraints or upstream supply challenges that can jeopardize manufacturing schedules, particularly when a sole supplier is unable to scale output reliably.
- Geopolitical, geographic, or environmental risk, including trade tensions, export controls, transportation disruptions, or exposure to natural disasters, can threaten supply when APIs are sourced from a single country or region, making geographic diversification a critical risk-control measure.
- Increasing demand or new market needs, such as transitions from clinical to commercial scale, label expansions, or entry into new geographies, often outpace the capacity of a single API supplier, especially for long lead-time or complex APIs, and warrant parallel qualification of a backup source.
- Supplier business or financial instability, including mergers and acquisitions, plant closures, layoffs, portfolio reprioritization, or declining commercial incentive, can lead to abrupt API discontinuation; without a second source vetted for capacity and long-term viability, manufacturers may face urgent and costly replacement efforts.
Taken together, operational, geopolitical, and supplier signals can indicate when qualifying a second API supplier should be prioritized.
***This is the end of part 1 on “When and Why to Qualify a Second API Source”. To continue reading this blog, please head over to part 2***